Drug intelligence / Profile preview

kava

Development stage
Phase 2
Lead developer
Thorne HealthTech
Modality
Small Molecules
Administration
Oral
01

Overview

Kava is a botanical extract derived from the roots of the *Piper methysticum* plant, native to the South Pacific. It is widely utilized as a dietary supplement and traditional medicine for its anxiolytic, sedative, and muscle-relaxant properties. The primary bioactive constituents are a group of lactones known as kavalactones, including kavain, dihydrokavain, and methysticin. These compounds exert their effects through several mechanisms, most notably the positive allosteric modulation of GABA-A receptors, which enhances inhibitory neurotransmission. Additionally, kavalactones inhibit voltage-gated sodium and calcium channels and provide reversible inhibition of monoamine oxidase B (MAO-B). While effective for managing mild-to-moderate anxiety disorders, kava has been subject to regulatory scrutiny and temporary bans in various jurisdictions due to reports of potential hepatotoxicity.

Brand names
LaitanKava-GulapaAntaresKavasedon
Other names
Piper methysticumKava-kavaAvaYaqonaSakauIntoxicating Pepper
02

Targets

GABRR (GABA-A receptor subunit rho)NET (Norepinephrine Transporter)MAOB (Monoamine oxidase B)CaV (Voltage-gated calcium channel protein complex)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on kava.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kava.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call